Verve Therapeutics (VERV) Earnings Date & Reports

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

VERV is expected to report earnings to rise 11.57% to -64 cents per share on May 07

Verve Therapeutics VERV Stock Earnings Reports

Q1'25

Est.

$-0.65

Q4'24

Beat

by $0.10

Q3'24

Beat

by $0.09

Q2'24

Beat

by $0.09

Q1'24

Beat

by $0.11

The last earnings report on February 27 showed earnings per share of -57 cents, beating the estimate of -68 cents. With 2.08M shares outstanding, the current market capitalization sits at 263.72M.

View a ticker or compare two or three

Compare

VERV